The group’s new platelet-rich plasma (PRP) offering meets international standards for compliance, safety, and efficacy
MIAMI LAKES, Florida—Adimarket, LLC, a subsidiary of the Global Stem Cells Group, today announced the availability of a new product that is a viable treatment option in a host of regenerative medicine sectors. With its new platelet-rich plasma (PRP) product, Adimarket will provide physicians with an exciting treatment protocol that can deliver relief to patients needing critical aesthetic, wound, and orthopedic care.
PRP is a super biological product of sorts, composed of a higher concentration of platelets than what is usually found in blood — 6-10 times more, on average. Adimarket’s PRP kit is the first of its kind in the stem cells and regenerative medicine industry, seeking to deliver higher platelet counts in an affordable and easy-to-use system. The revolutionary system is designed to shorten total processing time and reduce human error as it maximizes platelet concentration numbers. Adimarket’s offering has the capability of producing both leukocyte-rich and leukocyte-poor PRP and works in a variety of centrifuge systems.
PRP has been gaining interest and traction in the world of stem cell therapies and regenerative medicine. For clinicians working in the aesthetics, wound care, and orthopedic sectors, PRP has proven be a promising treatment option in offering relief to their patients.
In developing its PRP product, Adimarket researchers and scientists adhered to the highest international standards, making the product a viable option for physicians across the globe. With the launch of this new product, Adimarket is looking to expand its reach into new markets across the Middle East and Europe.
“Adimarket and its products have been met with great enthusiasm from physicians in the US and Latin America,” said Benito Novas, CEO of the Global Stem Cells Group. “With the launch of this new PRP product, our goal is to continue to serve our partners in those markets while expanding our presence into Europe and the Middle East. Our ultimate goal is to help more physicians across the globe deliver critical stem cell treatments to their patients, with the goal of alleviating unnecessary suffering.”